Viropharma, Inc. (VPHM) Tops Q3 EPS by 23c; Guides FY11 Cinryze Net Sales
Tweet
Share
E-mailGet Alerts VPHM Hot Sheet
Price: $49.96 --0%
Financial Fact:
Cost of sales (excluding amortization of product rights): 27.48M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Financial Fact:
Cost of sales (excluding amortization of product rights): 27.48M
Today's EPS Names:
OFLX, VAXX, NMRD, More
Join SI Premium – FREE
Viropharma, Inc. (NASDAQ: VPHM) reported Q3 EPS of $0.56, $0.23 better than the analyst estimate of $0.33. Revenue for the quarter came in at $143 million versus the consensus estimate of $129.47 million.
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Sees FY11 Cinryze net sales to be between $250 and $260 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
- Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c
- Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
